Report Highlights

Theranostics in the United States: Market Overview

The U.S. theranostics market pairs diagnostic PET imaging with targeted radioligand therapy, using matched agents such as Netspot and Lutathera for somatostatin-receptor-positive neuroendocrine tumors and Pluvicto for PSMA-positive metastatic prostate cancer. Valued at USD 4.2 billion in 2024, it represents the largest national theranostics base in the world. Its scale reflects dense PET-capable hospital infrastructure and early FDA approvals that established a diagnostic-first treatment pathway. Commercial activity concentrates in academic cancer centers and large community hospital systems.

Relative to the global norm, the United States differs in how adoption is financed and licensed. European buyers typically face national reimbursement negotiation, whereas U.S. providers depend on Medicare Part B drug payment and the CMS per-day threshold for separately payable diagnostic radiopharmaceuticals, set at USD 630 for 2024. Every site must also hold a Nuclear Regulatory Commission or Agreement State byproduct material license under 10 CFR Part 35, making delivery logistics a site-level constraint rather than a national one.

Growth Drivers in U.S. Theranostics

The first driver is diagnostic uptake of PSMA PET. The FDA approved Pylarify in May 2021 and Illuccix in December 2021, and NCCN guidelines now recommend PSMA-directed imaging for staging and biochemical recurrence. The American Cancer Society projected roughly 299,000 new U.S. prostate cancer cases in 2024, creating a large pool of candidates for imaging and subsequent Pluvicto therapy. Pluvicto's March 2022 approval extended this pathway to treatment.

The second and third drivers are reimbursement and isotope policy. CMS separate payment for diagnostic radiopharmaceuticals above the per-day threshold keeps PET agents financially viable in outpatient settings. Meanwhile the DOE Isotope Program, administered by the Office of Science, is expanding domestic production of actinium-225 and lutetium-177 to reduce dependence on imported supply and support alpha-emitting pipelines. Neuroendocrine tumor incidence also continues to rise, extending demand for Lutathera and Netspot beyond prostate cancer.

Market Restraints and Entry Barriers

Licensing and logistics form the first barrier. Lutetium-177 has a 6.7-day half-life and actinium-225 a 9.9-day half-life, so doses must be shipped under Type A packaging and dispensed on tight schedules by licensed nuclear pharmacies. Entrants must also secure a radioactive materials license from the NRC or an Agreement State, with separate authorization for each treatment site, which typically adds months to market access. Dose windows are measured in hours once a dose leaves the production site, and a missed delivery wastes a dose that costs thousands of dollars.

Incumbent advantage and payment rules compound the barrier. Novartis holds the approved PSMA therapy position with Pluvicto and an established Lutathera franchise, while Medicare prior authorization and site-of-care rules delay adoption at community hospitals. Pricing is also contested: Pluvicto launched at USD 42,500 per dose, and payers apply utilization controls that new entrants must navigate with evidence of cost offset from imaging-led patient selection. Isotope supply concentration adds a third risk, since few producers supply lutetium-177 at GMP scale.

Market Opportunities in the United States

The nearest entry window lies in actinium-225 alpha therapy. Bristol Myers Squibb, which acquired RayzeBio, and AstraZeneca, which acquired Fusion Pharmaceuticals, are advancing Ac-225 candidates that require new U.S. isotope supply chains and nuclear pharmacy capacity. The American Cancer Society estimated 35,250 U.S. prostate cancer deaths in 2024, a population where PSMA-directed therapy addresses metastatic disease. Suppliers able to deliver Ac-225 in volume will command pricing power.

Community and regional nuclear pharmacy capacity offers a second window. Health systems outside major metros often lack in-house PET and therapy dispensing, and an entrant securing Cardinal Health or PETNET Solutions distribution could serve dozens of satellite hospitals. Analyst estimates place addressable outpatient therapy dispensing demand at roughly USD 600 million by 2028.

Market at a Glance

Leading Market Participants

• Novartis
• Eli Lilly and Company
• Bristol Myers Squibb
• AstraZeneca
• Telix Pharmaceuticals
• Lantheus Holdings
• Curium US
• Cardinal Health
• PETNET Solutions
• Jubilant Radiopharma

Regulatory and Policy Environment

Radiopharmaceuticals are regulated as drugs by the FDA's Center for Drug Evaluation and Research, which reviews new drug applications under the Federal Food, Drug, and Cosmetic Act, with a standard ten-month goal after a sixty-day filing review. Manufacturing follows 21 CFR Part 212 current good manufacturing practice for PET drugs, while the Nuclear Regulatory Commission and Agreement States license byproduct material under 10 CFR Part 35. Site licensing and amendments add several months to launch timelines.

Reimbursement sits under the Centers for Medicare and Medicaid Services, which pays separately for diagnostic radiopharmaceuticals whose per-day cost exceeds USD 630 under the Hospital Outpatient Prospective Payment System, and pays therapeutic radioligands at average sales price plus six percent under Part B. The Department of Energy's Isotope Program funds domestic production of actinium-225 and related isotopes through research grants and supply partnerships rather than direct price subsidies. Entrants should align NDA timelines with CMS quarterly pricing updates.

Long-Term Outlook for U.S. Theranostics

By 2032 the U.S. market is projected to reach USD 11.8 billion, growing at a 13.8% CAGR from the 2025 base year. Growth will concentrate in PSMA-directed therapy moving into earlier-stage prostate cancer, and in actinium-225 candidates from Bristol Myers Squibb and AstraZeneca if Phase 3 readouts support approval within the forecast window. Lutathera and Netspot will keep neuroendocrine tumor demand steady across community networks.

Consolidation will continue as large pharma buys radioligand developers, and nuclear pharmacy networks will become a competitive asset. Commercial success will depend on whether companies secure isotope supply, win payer coverage for imaging-led patient selection, and build NRC-compliant dispensing across satellite hospitals. Entrants that establish these three capabilities by 2030 will hold durable share through 2032. The U.S. will remain the commercial reference market for global theranostics pricing throughout the period.